NIP
HOWL icon

Nicholas Investment Partners’s Werewolf Therapeutics HOWL Stock Holding History

Nicholas Investment Partners’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-296,283
Closed -$5.08M – 202
2021
Q3 		$5.08M Buy
296,283
+1,629
+0.6% +$27.8K 0.37% 99
2021
Q2 		$5.14M Buy
+294,654
New +$4.04M 0.32% 97

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Nicholas Investment Partners's HOWL Position: Q4 2021 in Review

Nicholas Investment Partners sold out of Werewolf Therapeutics (HOWL) in Q4 2021, closing a stake of 296,283 shares — an estimated $5.08M sold.

Nicholas Investment Partners first reported a position in HOWL in Q2 2021 and held it in 2 quarters. The position peaked at $5.14M in Q2 2021. 51 funds tracked by Wall St. Rank hold HOWL as of Q4 2021.

  • Nicholas Investment Partners reported no remaining Werewolf Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Nicholas Investment Partners sold 296,283 Werewolf Therapeutics shares in Q4 2021, an estimated $5.08M.
  • Nicholas Investment Partners first reported a position in Werewolf Therapeutics in Q2 2021 and held it in 2 quarters.
  • Nicholas Investment Partners's Werewolf Therapeutics position peaked at $5.14M in Q2 2021.
  • 51 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q4 2021.

Based on Nicholas Investment Partners's 13F filing for Q4 2021, filed 14 Feb 2022.